HCPCS Code J2405: Injection, Ondansetron Hydrochloride, per 1 mg

Key Takeaways

HCPCS Code J2405 describes Injection, ondansetron hydrochloride, per 1 mg – a Level II J-code used to bill the injectable form of this 5-HT3 antiemetic across oncology, PACU, and infusion settings

Billing is per 1 mg unit: a 4 mg dose requires 4 units of J2405. Miscounting units is the most common reason for claim denials and overpayment audits on this code

Coverage code D applies, meaning special coverage instructions govern reimbursement – always verify Local Coverage Determinations before submitting, as blanket coverage is not guaranteed

Pabau’s claims management software helps infusion and oncology clinics track injectable drug units accurately, reducing J-code denials and supporting compliant billing workflows

Ondansetron denials rarely come from wrong diagnosis codes. They come from wrong unit counts. A clinic administers 8 mg of ondansetron hydrochloride intravenously, bills two units of J2405 (the correct count is 8 units: 8 mg ÷ 1 mg per unit), and wonders why the claim bounces. The answer is straightforward once you understand how HCPCS Code J2405 is structured – but coders who miss the per-1-mg unit logic will keep generating the same errors on every infusion encounter.

This reference guide covers everything billers, coders, and clinic administrators need to submit J2405 claims correctly: the official code description, unit calculation with worked examples, NDC crosswalk requirements, documentation expectations, applicable modifiers, and 2026 Medicare reimbursement context.

HCPCS Code J2405: Definition and Clinical Description

According to the Centers for Medicare and Medicaid Services (CMS), HCPCS Code J2405 is maintained as a Level II J-code within the “Drugs Administered Other than Oral Method” category. The official long description reads: Injection, ondansetron hydrochloride, per 1 mg. The short description, used in most billing systems, is Ondansetron hcl injection.

Ondansetron hydrochloride is a selective 5-HT3 receptor antagonist. It works by blocking serotonin receptors in the small intestine and chemoreceptor trigger zone, making it one of the most widely used agents for chemotherapy-induced nausea and vomiting (CINV), post-operative nausea and vomiting (PONV), and radiation-induced nausea. The FDA approved ondansetron in 1991, per the NLM Clinical Tables HCPCS database. The brand name Zofran has since been discontinued; billers who have hard-coded NDC numbers tied to the Zofran NDC should update them to reflect the generic manufacturer NDC currently in use.

J2405 was added to the HCPCS on January 1, 1993. Its action code is N (no maintenance required), effective January 1, 1997. Coverage code D applies, meaning special coverage instructions govern payer decisions. Clinics using claims management software that automatically flags coverage code D codes for LCD verification before submission can avoid a significant share of preventable denials.

Code Properties at a Glance

The table below summarizes the key administrative properties of HCPCS Code J2405 as maintained in the CMS HCPCS code file.

Units Billing and Dose Calculation for J2405

The most operationally significant aspect of HCPCS Code J2405 is its per-1-mg unit structure. One unit of J2405 equals one milligram of ondansetron hydrochloride administered. This is not a per-vial or per-encounter code. Billing the wrong number of units is the leading cause of J2405 claim denials across Medicare, Medicaid, and commercial payers.

Unit Calculation Examples

Use the following examples to verify your billing before submission. These align with payer guidance published by Amerigroup in their NDC billing FAQ for providers:

• 4 mg dose administered: Bill 4 units of J2405
• 8 mg dose administered: Bill 8 units of J2405
• 2 mg dose from a 2 mg/ml vial (2 ml): Bill 2 units of J2405
• Partial vial (1 mg used from a 4 mg/2 ml vial): Bill 1 unit of J2405; document wastage with modifier JW or JZ depending on payer policy

Clinics drawing from multi-dose vials must confirm the actual administered volume against the vial concentration before determining units. A 40 mg/20 ml vial yields a 2 mg/ml concentration. If 4 ml is administered (8 mg), the billing should reflect 8 units. Errors typically happen when staff record administered volume rather than administered milligrams. Building dose-to-unit conversion into your clinical records workflow removes this manual calculation from the billing step.

Drug Wastage: Modifiers JW and JZ

When a single-dose vial is partially used and the remainder is discarded, some payers require reporting the wasted portion. Modifier JW identifies the discarded drug amount billed separately. Modifier JZ, introduced more recently, indicates that no drug was wasted (zero wastage). Requirements vary significantly by payer. Medicare requires JW when billing wasted drugs from single-dose vials. Some Medicaid managed care plans require JZ on claims with no wastage for audit verification. Always check the applicable Local Coverage Determination (LCD) and payer-specific policy before applying these modifiers. The compliance management tools in your practice management system can help flag which modifier applies per payer profile.

NDC Crosswalk for HCPCS Code J2405

Many payers, including Medicaid managed care organizations, require a National Drug Code (NDC) to accompany HCPCS Code J2405 on the claim. The NDC identifies the specific manufacturer product used, while J2405 identifies the type of service. These are complementary, not redundant.

Multiple NDC codes are associated with J2405 because ondansetron is manufactured by several generic pharmaceutical companies in various vial sizes and concentrations. The brand-name Zofran NDC has been discontinued; clinics that still have it hard-coded into their drug inventory systems will generate claim rejections on Medicaid and commercial plans that validate NDC-to-HCPCS crosswalk accuracy.

NDC Billing Format on Claims

When reporting an NDC on a claim, the format matters. On CMS-1500 paper claims and 837P electronic claims, the NDC is reported in the qualifier field with:

• Qualifier: N4 (for NDC)
• NDC number: 11-digit format (5-4-2 segments, no hyphens in electronic submission)
• Unit qualifier: ML (milliliters) or UN (units), per the payer’s NDC billing instructions
• Quantity: The number of units in the unit-of-measure selected

For example, if you administer 4 mg of ondansetron from a vial with NDC 00143986901 (Hikma/West-Ward ondansetron 2 mg/mL, 20 mL multi-dose vial), you report J2405 with 4 units on the HCPCS line, and N4-00143986901-ML-2 (2 ml administered) on the NDC line. Always confirm unit qualifier requirements with the specific payer, as some require UN (units administered) rather than ML. Refer to the AAPC Codify HCPCS lookup to verify the current crosswalk table for J2405.

Track Injectable Drug Units Accurately with Pabau

Pabau's claims management tools help infusion clinics link administered drug volumes to billing units automatically, reducing J-code denials and supporting NDC crosswalk compliance across all payers.

Book a demo

Documentation Requirements

Coverage code D on J2405 means payers apply specific coverage instructions rather than providing blanket reimbursement. Documentation that supports medical necessity is therefore not optional. A claim without supporting clinical documentation can be denied even if the code and units are technically correct.

The clinical record must establish that ondansetron was medically necessary for the encounter. Relevant documentation elements include the patient’s diagnosis (with supporting intake documentation and a clearly recorded ICD-10 code), the ordered dose, route of administration, date and time of administration, and the name of the administering clinician.

Supported ICD-10 Diagnosis Codes

The following ICD-10 codes are commonly paired with J2405. Payer LCDs may specify additional covered diagnoses or restrict coverage to particular indications:

• R11.0: Nausea
• R11.10: Vomiting, unspecified
• R11.11: Vomiting without nausea
• R11.2: Nausea with vomiting, unspecified
• T45.1X5A: Adverse effect of antineoplastic and immunosuppressive drugs (chemotherapy-induced nausea, initial encounter)

For chemotherapy-related indications, payers generally apply more permissive coverage. For PONV in outpatient surgical settings, coverage may depend on place of service and whether the facility is billing separately for the drug. Oncology and IV therapy clinics billing J2405 in an office or infusion center setting should verify their MAC’s applicable LCD for nausea and antiemetic drugs before billing.

Place of Service and Revenue Code Considerations

Place of service (POS) code affects reimbursement. J2405 billed from a physician office (POS 11) is reimbursed under the Medicare Physician Fee Schedule (MPFS). When billed from a hospital outpatient department (POS 22), reimbursement falls under the Outpatient Prospective Payment System (OPPS). Hospital outpatient claims also require revenue code 0636 (drugs requiring specific identification) on the UB-04. Confirm POS and revenue code requirements with your billing clearinghouse and your MAC before the first submission from a new site of service.

Reimbursement Rates, Modifiers, and Payer-Specific Guidelines

Medicare reimburses J2405 under the Average Sales Price (ASP) methodology. CMS updates ASP-based drug reimbursement quarterly; the published rate reflects ASP plus a 6% add-on for non-excepted Part B drugs administered in office and outpatient settings. Because rates change quarterly, always verify current allowable amounts through the CMS Physician Fee Schedule lookup tool rather than relying on cached fee schedule data in your billing system.

Medicaid rates vary by state and managed care organization. Commercial payer contracts typically reimburse at either Average Wholesale Price (AWP) minus a contracted percentage or a fixed per-unit rate negotiated in the provider agreement. Verify your current contracted rate for J2405 by reviewing the drug fee schedule attachment in your payer agreement. Discrepancies between the contracted rate and the remittance amount are grounds for a timely billing dispute under most plan terms.

Applicable Modifiers for J2405

Select modifiers carefully. Incorrect modifier use is a common audit trigger on J-code claims:

• JW: Drug amount discarded (wasted portion from single-dose vial) – required by Medicare, rules vary by payer
• JZ: Zero drug wastage – confirms full vial was used; some payers require this when no wastage occurs
• 59: Distinct procedural service – use when J2405 is billed alongside another drug or service on the same date and payer edits bundle them incorrectly
• GY: Item or service statutorily excluded from Medicare – use only when billing a non-covered indication for secondary payer purposes
• GA: Waiver of liability statement on file – use when an Advance Beneficiary Notice (ABN) has been signed and coverage is uncertain
• KX: Requirements specified in the LCD have been met – required by some MACs when billing under an applicable LCD for antiemetic drugs

Never stack JW and JZ on the same claim line. These modifiers are mutually exclusive. If your IV therapy clinic treats multiple patients from the same multi-dose vial in a single session, document actual wastage per patient encounter rather than estimating at the end of the day. Retrospective wastage documentation is a significant audit flag for the clinical documentation auditors at the Office of Inspector General (OIG).

Common Denial Reasons and How to Prevent Them

J2405 denials fall into predictable categories. Addressing the root cause in your billing workflow prevents recurrence:

• Incorrect unit count: Administered dose recorded in ml, not mg. Fix: require mg documentation at point of care
• Missing or outdated NDC: Hard-coded Zofran NDC flagged as invalid. Fix: update NDC to current generic manufacturer code
• Unsupported diagnosis: ICD-10 code not covered under payer LCD. Fix: verify covered indications before submitting
• No prior authorization: Some commercial plans require PA for antiemetics outside oncology. Fix: pre-authorize when payer contract requires it
• Place of service mismatch: Drug billed under POS 11 but administered in a hospital outpatient setting. Fix: confirm POS before claim generation
• Missing wastage modifier: Single-dose vial partially used, no JW reported. Fix: build modifier prompts into your infusion nursing workflow

Practices using integrated claims management with built-in payer-rule edits can catch most of these errors before the claim leaves the system. Pre-submission scrubbing that flags J2405 claims without an NDC, without a supported diagnosis, or with a unit count that doesn’t correspond to a documented dose eliminates the denial-and-rework cycle entirely.

Expert Picks

Need a billing framework for your IV therapy clinic? Best EMR for IV Therapy covers how purpose-built EMR platforms handle infusion drug documentation and J-code billing more accurately than general EHRs.

Looking for guidance on running a compliant infusion operation? IV Therapy Clinic Best Practices outlines the operational and documentation standards that reduce billing risk in infusion settings.

Want to streamline drug administration documentation across your clinic? Pabau Client Records lets clinical teams capture administered dose, route, and diagnosis in a structured encounter note that feeds directly into the billing workflow.

Conclusion

The most preventable revenue losses on J2405 claims share a single cause: units calculated in the wrong denominator. Once a team internalizes the per-1-mg structure of HCPCS Code J2405, most billing errors resolve at the point of documentation rather than at the denial stage. The secondary layer – NDC accuracy, modifier discipline, and coverage code D compliance – requires payer-specific verification but follows a repeatable process once built into the workflow.

Pabau’s claims management software helps infusion and oncology clinics connect administered drug documentation to billing units automatically, reducing the manual calculation step where most J-code errors originate. To see how Pabau handles injectable drug billing for your clinic type, book a demo.

Frequently Asked Questions